United Therapeutics Corp Stock Research

Market Summary

USD217.22+3.74

Market Closed

1.75%

UTHR Alerts

2 major insider sales recently.

UTHR Stock Price

UTHR RSI Chart

UTHR Valuation

Market Cap

10.1B

Price/Earnings (Trailing)

13.95

Price/Sales (Trailing)

5.12

EV/EBITDA

8.74

Price/Free Cashflow

14.05

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

49.09%

Return on Equity

15.16%

Return on Assets

12.03%

Free Cashflow Yield

7.12%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

9.74%

Revenue Q/Q

3.13%

UTHR Earnings

Earnings (TTM)

727.3M

Earnings Y/Y

17.74%

Earnings Q/Q

-44.8%

Price Action

52 Week Range

201.65283.09

(Low)(High)

Last 7 days

4.8%

Last 30 days

-0.5%

Last 90 days

-12.6%

Trailing 12 Months

-4.8%

UTHR Financial Health

Current Ratio

9.85

UTHR Investor Care

Shares Dilution (1Y)

3.12%

Diluted EPS (TTM)

14.83

Peers (Alternatives to United Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	309.8B	1.6B	-14.20%	63.79%	-161.61	198.97	77.54%	1.62%
ABBV	285.4B	56.7B	-8.29%	-4.90%	24.12	4.92	0.03%	-39.22%
REGN	87.6B	12.4B	-7.87%	17.32%	20.2	7.2	-25.07%	-47.28%
VRTX	86.0B	9.2B	-3.63%	23.60%	26.37	9.33	15.86%	32.99%
ALNY	24.1B	1.0B	-2.92%	54.32%	-22.59	23.19	22.88%	-19.27%
SRPT	11.7B	975.7M	-0.22%	72.44%	-10.45	11.95	27.41%	-212.78%
UTHR	10.1B	2.0B	-0.54%	-4.82%	13.95	5.12	12.05%	52.86%
MID-CAP
MDGL	4.8B	-	-14.71%	282.83%	-15.1	2.5K	-	-27.52%
RARE	3.6B	363.3M	17.36%	1.78%	-5.05	9.82	3.39%	-55.81%
BPMC	3.5B	204.6M	12.22%	2.64%	-6.05	17.19	-7.52%	10.65%
MRTX	2.2B	18.9M	-15.43%	-4.97%	-3.02	117.75	-	-16.17%
SMALL-CAP
CYTK	3.7B	-	-1.80%	-6.60%	-8.5	38.73	34.30%	-67.22%
CPRX	1.2B	256.5M	-30.42%	62.68%	12.31	4.77	66.85%	120.61%
MGNX	300.5M	165.3M	-29.46%	47.27%	-3.29	1.82	130.70%	57.97%
CRBP	41.5M	-	15.88%	3252.62%	-0.82	19.11	-	-29.84%

Financials for United Therapeutics

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	2.3%	1,981	1,936	1,860	1,789	1,768
Gross Profit	3.7%	1,723	1,661	1,633	-	-
S&GA Expenses	-4.3%	480	501	-	-	-
R&D Expenses	4.3%	337	323	312	325	305
Costs and Expenses	5.1%	1,005	957	886	900	860
EBITDA	4.7%	1,034	988	875	939	-
EBITDA Margin	0.6%	0.53*	0.53*	0.49*	0.53*	-
Earnings Before Taxes	-1.8%	934	951	912	804	870
EBT Margin	0.1%	0.49*	0.49*	0.45*	0.49*	-
Interest Expenses	28.1%	42.00	32.00	25.00	20.00	19.00
Net Income	2.8%	727	707	631	687	-
Net Income Margin	-1.2%	0.38*	0.38*	0.35*	0.39*	-
Free Cahsflow	-2.3%	664	679	652	673	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	5.0%	6,346	6,045	5,782	5,543	5,360
Current Assets	-5.5%	3,193	3,380	3,056	2,684	2,587
Cash Equivalents	21.0%	1,164	961	967	795	813
Inventory	0.5%	103	102	91.00	90.00	88.00
Net PPE	4.1%	897	862	841	791	784
Liabilities	-2.0%	1,223	1,248	1,219	1,225	1,184
Current Liabilities	-5.4%	325	343	316	332	293
Shareholder's Equity	6.8%	5,123	4,797	4,562	4,318	4,176
Retained Earnings	4.8%	5,283	5,042	4,910	4,671	4,555
Additional Paid-In Capital	2.9%	2,457	2,388	2,315	2,292	2,254
Accumulated Depreciation	3.4%	377	364	352	-	-
Shares Outstanding	1.4%	47.00	46.00	46.00	45.00	45.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	10.7%	889	803	849	776	797
Share Based Compensation	8.1%	116	107	87.00	114	77.00
Cashflow From Investing	17.0%	-673	-811	-818	-959	-839
Cashflow From Financing	79.0%	135	75.00	27.00	37.00	24.00

Risks for UTHR

What is the probability of a big loss on UTHR?

72.3%

Probability that United Therapeutics stock will be more than 20% underwater in next one year

28.1%

Probability that United Therapeutics stock will be more than 30% underwater in next one year.

12.7%

Probability that United Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does UTHR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if United Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for UTHR

Cumulative Returns on UTHR

12.8%

10-Year Cumulative Returns

9.3%

7-Year Cumulative Returns

15.2%

5-Year Cumulative Returns

20.8%

3-Year Cumulative Returns

What are the long-term rolling returns for UTHR?

FIve years rolling returns for United Therapeutics.

Annualized Returns

Which funds bought or sold UTHR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-06-01	MACQUARIE GROUP LTD	reduced	-21.34	-12,176,000	20,725,000	0.03%
2023-05-30	Aspire Private Capital, LLC	reduced	-10.34	-2,242	5,823	-%
2023-05-26	ProShare Advisors LLC	reduced	-18.51	-694,535	1,326,070	-%
2023-05-23	BROOKFIELD Corp /ON/	sold off	-100	-7,932,520	-	-%
2023-05-23	Seaport Global Advisors, LLC	added	8.33	-69,001	471,884	1.49%
2023-05-23	ROYCE & ASSOCIATES LP	unchanged	-	-541,300	2,239,600	0.02%
2023-05-23	Capital Impact Advisors, LLC	sold off	-100	-277,534	-	-%
2023-05-23	Toroso Investments, LLC	added	190	3,499,000	6,108,000	0.10%
2023-05-22	Raleigh Capital Management Inc.	sold off	-100	-10,289	-	-%
2023-05-22	EMC Capital Management	unchanged	-	-136,000	563,000	0.47%

Latest Funds Activity

Are funds buying UTHR calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own UTHR

No. of Funds

UTHR Alerts

2 major insider sales recently.

United Therapeutics News

Schedule 13G FIlings of United Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2023	blackrock inc.	10.2%	4,726,986	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	6.3%	2,865,000	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.14%	2,344,492	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.83%	4,480,719	SC 13G/A
Feb 06, 2023	wellington management group llp	5.64%	2,569,263	SC 13G
Feb 02, 2023	rothblatt martine a	8.0%	3,919,603	SC 13G/A
Jan 24, 2023	blackrock inc.	9.9%	4,510,211	SC 13G/A
Feb 11, 2022	renaissance technologies llc	6.48%	2,917,191	SC 13G/A
Feb 11, 2022	avoro capital advisors llc	6.7%	3,035,000	SC 13G/A

UTHR Fair Value

Show Fair-Value

Recent SEC filings of United Therapeutics

View All Filings

Date Filed	Form Type	Document
Jun 01, 2023	144	Notice of Insider Sale Intent
Jun 01, 2023	4	Insider Trading
May 31, 2023	SD	SD
May 23, 2023	4	Insider Trading
May 18, 2023	144	Notice of Insider Sale Intent
May 18, 2023	4	Insider Trading
May 11, 2023	4	Insider Trading
May 08, 2023	4	Insider Trading
May 05, 2023	144	Notice of Insider Sale Intent
May 04, 2023	144	Notice of Insider Sale Intent

Latest Insider Trading transactions for UTHR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-06-01	MAHON PAUL A	sold	-1,254,680	209	-6,000	evp & general counsel
2023-06-01	MAHON PAUL A	acquired	721,560	120	6,000	evp & general counsel
2023-05-22	Giltner Richard	acquired	319,500	63.9	5,000	-
2023-05-22	Giltner Richard	back to issuer	-1,092,950	218	-5,000	-
2023-05-18	MAHON PAUL A	sold	-1,287,470	214	-6,000	evp & general counsel
2023-05-18	MAHON PAUL A	acquired	721,560	120	6,000	evp & general counsel
2023-05-10	PATUSKY CHRISTOPHER	back to issuer	-424,480	212	-2,000	-
2023-05-10	PATUSKY CHRISTOPHER	acquired	176,060	88.03	2,000	-
2023-05-05	Mesa Nilda	sold	-80,337	214	-374	-
2023-05-04	MAHON PAUL A	sold	-1,294,900	215	-6,000	evp & general counsel

About United Therapeutics

Martine A. Rothblatt

www.unither.com

960

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Income Statement

2023-03-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Total revenues	$ 506.9	$ 461.9
Operating expenses:
Cost of sales	52.3	25.9
Research and development	82.9	69.0
Selling, general, and administrative	87.3	79.0
Total operating expenses	222.5	173.9
Operating income	284.4	288.0
Interest income	29.2	4.3
Interest expense	(13.8)	(4.7)
Other (expense) income, net	(7.9)	22.8
Impairment of investment in privately-held company	0.0	(1.7)
Total other income, net	7.5	20.7
Income before income taxes	291.9	308.7
Income tax expense	(51.0)	(68.8)
Net income	$ 240.9	$ 239.9
Net income per common share:
Basic (in dollars per share)	$ 5.20	$ 5.31
Diluted (in dollars per share)	$ 4.86	$ 5.03
Weighted average number of common shares outstanding:
Basic (in shares)	46.3	45.2
Diluted (in shares)	49.6	47.7

UTHR Balance Sheet

2023-03-31

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,163.5	$ 961.2
Marketable investments	1,699.9	1,877.5
Accounts receivable, no allowance for 2023 and 2022	134.5	220.4
Inventories, net	102.5	102.0
Other current assets	92.6	219.2
Total current assets	3,193.0	3,380.3
Marketable investments	1,765.6	1,316.2
Goodwill and other intangible assets, net	44.5	44.5
Property, plant, and equipment, net	896.5	861.5
Deferred tax assets, net	321.9	327.7
Other non-current assets	124.5	114.3
Total assets	6,346.0	6,044.5
Current liabilities:
Accounts payable and accrued expenses	239.7	229.9
Share tracking awards plan	46.3	80.8
Other current liabilities	38.6	32.5
Total current liabilities	324.6	343.2
Line of credit	800.0	800.0
Other non-current liabilities	98.2	104.6
Total liabilities	1,222.8	1,247.8
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued	0.0	0.0
Common stock, par value $.01, 245,000,000 shares authorized, 73,317,754 and 72,651,280 shares issued, and 46,698,538 and 46,032,064 shares outstanding as of March 31, 2023 and December 31, 2022, respectively	0.7	0.7
Additional paid-in capital	2,457.3	2,388.4
Accumulated other comprehensive loss	(38.8)	(55.5)
Treasury stock, 26,619,216 shares as of March 31, 2023 and December 31, 2022	(2,579.2)	(2,579.2)
Retained earnings	5,283.2	5,042.3
Total stockholders’ equity	5,123.2	4,796.7
Total liabilities and stockholders’ equity	$ 6,346.0	$ 6,044.5